Brokerages Set iRadimed Corporation (NASDAQ:IRMD) Target Price at $120.00

Shares of iRadimed Corporation (NASDAQ:IRMD) have received a consensus recommendation of “Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $120.00.

A number of brokerages have recently issued reports on IRMD. Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday.

Insider Buying and Selling

In related news, Director Monty K. Allen sold 1,419 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the sale, the director owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. This trade represents a 6.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC acquired a new position in shares of iRadimed in the 2nd quarter valued at approximately $28,000. Farther Finance Advisors LLC lifted its stake in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 397 shares in the last quarter. IFP Advisors Inc lifted its stake in iRadimed by 264.7% in the second quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 413 shares in the last quarter. Quarry LP acquired a new position in shares of iRadimed in the third quarter valued at approximately $40,000. Finally, CWM LLC increased its position in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

iRadimed Price Performance

NASDAQ IRMD opened at $81.87 on Friday. The stock’s 50 day simple moving average is $91.10 and its 200 day simple moving average is $93.09. iRadimed has a one year low of $67.84 and a one year high of $107.90. The firm has a market cap of $1.05 billion, a PE ratio of 45.74 and a beta of 0.89.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities analysts expect that iRadimed will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were issued a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. iRadimed’s payout ratio is 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.